Positive Response to Fluorouracil and Oxaliplatin in Signet Ring Cell Adenocarcinoma of the Bladder Presenting With Retroperitoneal Fibrosis.
bladder cancer
signet cell bladder cancer
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
21 Jul 2020
21 Jul 2020
Historique:
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Bladder adenocarcinoma is an uncommon type of bladder cancer. Signet ring cell pathology is a rare subtype of bladder adenocarcinoma. Global incidence rates of signet ring cell adenocarcinoma of the bladder have not been established. Management of signet cell bladder cancer is challenging as it is aggressive in behavior with frequent relapse despite chemotherapy. Here we present a case of stage IV signet cell bladder cancer with retroperitoneal fibrosis treated with FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) regimen with a complete durable response.
Identifiants
pubmed: 32850200
doi: 10.7759/cureus.9322
pmc: PMC7444851
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e9322Informations de copyright
Copyright © 2020, Hinduja et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Urol Ann. 2012 May;4(2):98-101
pubmed: 22629005
Br J Urol. 1971 Feb;43(1):4-15
pubmed: 4926456
Urology. 2010 Mar;75(3):615-8
pubmed: 19819534
WMJ. 2006 May;105(3):55-8
pubmed: 16749327
J Urol. 2013 May;189(5):1656-61
pubmed: 23159581
Urol Int. 1995;55(1):34-7
pubmed: 7571182
Case Rep Urol. 2013;2013:915874
pubmed: 23738191